We propose a new hypothesis that the established drug pentoxifylline deserves attention as
a potential repurposed therapeutic for COVID‐19. Pentoxifylline is an immunomodulator with …

In December 2019, a new coronavirus, named severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), emerged from China, causing pneumonia outbreaks first in …

Background: COVID-19, caused by SARS-CoV-2, is a potentially lethal, rapidly-expanding
pandemic and many efforts are being carried out worldwide to understand and control the …

Rapidly spreading outbreak of the novel Severe Acute Respiratory Syndrome Coronavirus-2
(SARS-CoV-2) is causing serious health concerns worldwide. It started as an epidemic in …

Pentoxifylline (PTX) has broad-spectrum properties such as anti-inflammatory,
anticoagulant, and antiviral effects. The aim of this study was to evaluate the efficacy and …

COVID-19 pandemic presents an unprecedented challenge to identify effective drugs for
treatment. Despite multiple clinical trials using different agents, there is still a lack of specific …

We have previously hypothesized that pentoxifylline could be beneficial for the treatment of
COVID-19 given its potential to restore the immune response equilibrium, reduce the impact …

Accumulating evidence suggests that a subgroup of patients with COVID-19 might suffer
from severe complications, such as acute respiratory distress syndrome (ARDS) …

The outburst of inflammatory response and hypercoagulability are among the factors
contributing to increased mortality in severe COVID-19 cases. Pentoxifylline (PTX), a …

The existing pandemic viral infection caused by severe acute respiratory syndrome
coronavirus type 2 (SARS-CoV-2) leads to coronavirus disease 2019 (Covid-19). SARS …